Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Neladenoson Bialanate in Hepatic Impairment
NCT04322253Phase 1Terminated
- Sponsor
- Bayer
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of neladenoson bialanate in chronic heart failure (CHF) (3 arms), sponsored by Bayer. Primary endpoints: Fraction unbound for BAY 84-3174, Area Under the Curve for BAY 84-3174 at 49 days and 1 more. Started Aug 2017; status: terminated.
02
Drugs
neladenoson bialanate
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT04322253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322253.